Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis.
Hosana Candreva, Mehak Dang, Henrique Guimarães Barbosa Coelho et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis compared rituximab monotherapy with watchful waiting (WW) in adults with asymptomatic, advanced-stage, low-tumor-burden follicular lymphoma. Three studies—two randomised controlled trials and one observational study—included 1590 patients. Rituximab was not associated with a statistically significant difference in overall survival (HR 0.89, 95% CI 0.70-1.12; P = .31) or histological transformation (risk ratio 0.84, 95% CI 0.60-1.16; P = .29). Time to new treatment was longer with rituximab (HR 0.50, 95% CI 0.41-0.61; P < .00001).
Key findings
- Overall survival did not differ significantly between rituximab and WW (HR 0.89, 95% CI 0.70-1.12; P = .31; I² = 0%).
- Rituximab was not associated with a significant reduction in histological transformation (risk ratio 0.84, 95% CI 0.60-1.16; P = .29; I² = 0%).
- Time to new treatment was significantly prolonged with rituximab versus WW (HR 0.50, 95% CI 0.41-0.61; P < .00001; I² = 0%).
Why it matters
For asymptomatic patients with advanced-stage low-tumor-burden follicular lymphoma, the findings distinguish delaying subsequent treatment from demonstrating a survival or transformation benefit. This helps frame discussions of early rituximab against observation while underscoring that the reported advantage was in time to new treatment, not the primary survival outcome.
What to keep in mind
The meta-analysis included only three studies, one of which was observational; the authors call for further prospective studies to clarify long-term clinical impact.